Medical Device Skin Irritation Evaluation: Standards, Test Methods, and Regulatory Compliance

Skin irritation evaluation is a core element of the ISO 10993 biocompatibility testing program required for medical devices that contact patient tissue directly or indirectly. Performed primarily in accordance with ISO 10993-23, these studies determine whether device materials or their extracts induce local inflammatory responses such as erythema and edema. This article explains the applicable standards, sample preparation requirements, test methodologies, interpretation criteria, and regulatory applications of skin irritation testing for medical devices.

Technical Overview

Skin irritation is defined as the production of reversible localized inflammatory changes in the skin following direct contact with a medical device or its extractable constituents. The formation of erythema (redness), eschar (scabbing), and edema (swelling) are the primary endpoints evaluated in an irritation study. Because even materials intended only for brief skin contact can leach irritating substances, irritation testing is one of the fundamental biological endpoint tests in the ISO 10993 series of biocompatibility standards.

The evaluation strategy is driven by the risk-based framework of ISO 10993-1, which classifies devices according to the nature of body contact (surface devices, external communicating devices, or implant devices), the contacting tissue (intact skin, mucosal membrane, breached or compromised surface, blood, tissue/bone), and the cumulative contact duration (limited contact of up to 24 hours, prolonged contact from 24 hours to 30 days, and permanent contact exceeding 30 days). Irritation testing is generally expected for any device category with skin, mucosal, or breached-surface contact unless a documented scientific justification, supported by chemical characterization and existing data, demonstrates that the endpoint is adequately addressed.

Key Standards and References

• ISO 10993-1: Biological evaluation of medical devices – Evaluation and testing within a risk management process
• ISO 10993-23:2021: Biological evaluation of medical devices – Part 23: Tests for irritation, which superseded the irritation test methods previously covered by ISO 10993-10 (now focused on sensitization)
• ISO 10993-12: Sample preparation and reference materials, defining extraction vehicles, ratios, and conditions
• ISO 10993-2: Animal welfare requirements, mandating the principles of replacement, reduction, and refinement (the 3Rs)
• GB/T 16886 series (including GB/T 16886.23): the Chinese national standard series harmonized with ISO 10993, applicable to NMPA submissions
• OECD Test Guideline 439: In vitro skin irritation testing using reconstructed human epidermis (RhE) models
• ISO 14971: Application of risk management to medical devices, which frames the overall biological safety assessment

Testing Samples

Skin irritation studies can be performed on complete finished devices, device components, material coupons, or extracts prepared from the device. The sample form dictates the test design, as described below.

Devices Contacting Intact Skin

Surface medical devices intended for external communication with intact skin, such as electrode pads, compression cuffs, respiratory masks, adhesive tapes, orthopedic supports, wearable sensor housings, and insulin pump patches, are typically evaluated using direct-contact dermal application or extract-based methods, depending on the geometry and rigidity of the product.

Devices Contacting Breached Skin and Mucosal Membranes

Wound dressings, hydrogels, burn treatment products, catheter fixation devices, condoms, and intravaginal or urethral products require irritation evaluation against the relevant contact tissue. For breached-surface or mucosal-contacting devices, intracutaneous reactivity testing is frequently selected as a conservative surrogate because it assesses the irritant potential of extractable substances against living tissue.

Test Extracts and Direct-Contact Specimens

Extracts are prepared according to ISO 10993-12 using both a polar vehicle (such as 0.9% sodium chloride injection or water) and a non-polar vehicle (such as sesame oil or cottonseed oil). Common extraction parameters include:

• Standardized surface-area-to-volume ratios: 6 cm²/mL for materials thinner than 0.5 mm, 3 cm²/mL for materials 0.5 mm to 1.0 mm thick, and 0.1 g/mL or 0.2 g/mL for irregular, porous, or three-dimensional devices
• Extraction conditions: 37 ± 1 °C for 72 ± 2 hours, 50 ± 2 °C for 72 ± 2 hours, 70 ± 2 °C for 24 ± 2 hours, or 121 ± 1 °C for approximately 1 hour, selected to represent a worst-case yet non-degrading condition for the material
• Direct-contact testing of solid specimens cut to approximately 25 mm × 25 mm for patch application when the device surface itself is the contacting element

Testing Items

Depending on the device classification and the biological safety plan, the following irritation-related evaluations may be performed by accredited third-party laboratories or in-house biocompatibility facilities:

• Acute dermal irritation: single-application evaluation of erythema and edema following skin exposure, typically 4 hours under occlusive patches
• Intracutaneous (intradermal) reactivity: injection-based assessment of the irritant potential of device extracts
• Mucosal irritation: evaluation of responses in oral, vaginal, penile, rectal, or bladder tissue models where applicable
• Ocular irritation: assessment of devices or extracts with potential eye contact, often supported by in vitro methods
• Photoirritation: evaluation of irritation potential in the presence of light for devices containing photoreactive substances
• Repeated or cumulative exposure irritation: for devices with prolonged or permanent contact durations, per the requirements of ISO 10993-23

It is important to distinguish irritation testing from sensitization testing under ISO 10993-10. Irritation evaluates localized, acute inflammatory reactions, while sensitization evaluates delayed Type IV hypersensitivity, a systemic immune response. The two endpoints are complementary and are frequently performed together on the same extract sets.

Testing Methods

In Vivo Rabbit Dermal Irritation Test

The classical method described in ISO 10993-23 uses healthy adult rabbits (typically a minimum of three animals). The fur is clipped from the dorsal area, and 0.5 mL of test extract or a solid specimen is applied to 25 mm × 25 mm absorbent patches held in place with non-occluding or semi-occlusive dressings for a single exposure period of at least 4 hours, extendable up to 24 hours when clinically justified. Parallel sites receive the corresponding blank vehicle to serve as controls. Scoring is performed after patch removal and at approximately 24, 48, and 72 hours.

Intracutaneous Reactivity Test

For extract-based evaluation, 0.2 mL aliquots of each test extract are injected intradermally at five sites on one side of each rabbit, with the blank vehicle injected at five contralateral sites. Erythema and edema are graded at 24, 48, and 72 hours after injection. The reactivity score is calculated as the difference between the mean test-extract scores and the mean blank-control scores; a difference of 1.0 or less generally indicates that the device meets the reactivity requirements.

In Vitro Reconstructed Human Epidermis (RhE) Models

In line with the 3Rs principles and ISO 10993-2, validated in vitro alternatives based on reconstructed human epidermis tissues, consistent with OECD TG 439, may be used to screen for skin irritation potential. Device extracts are applied topically to the RhE tissue, and cytotoxicity is measured via MTT metabolic viability. Tissue viability remaining above the defined threshold relative to the negative control predicts a non-irritant classification. In vitro methods are subject to specific applicability restrictions, including limitations on extraction vehicles and conditions, and positive findings or borderline results are typically confirmed through in vivo testing.

Scoring and Interpretation

• Each application or injection site is graded on a 0 to 4 scale for erythema and eschar formation, and on a 0 to 4 scale for edema formation
• The Primary Irritation Index (PII) is calculated as the sum of all erythema and edema scores divided by the total number of scoring observations, yielding a value from 0.0 to 8.0
• Common interpretation bands: 0.0 to 0.4 negligible irritation, 0.5 to 1.9 slight irritation, 2.0 to 4.9 moderate irritation, and 5.0 to 8.0 severe irritation
• ISO 10993-23 additionally emphasizes comparison of the incidence, severity, and persistence of responses between test and control sites to support the final classification

Applications

Skin irritation evaluation data support a wide range of regulatory and quality objectives across the product lifecycle:

• Regulatory submissions to the US FDA, including 510(k), De Novo, and PMA applications, as part of the biocompatibility assessment section
• CE marking technical documentation under the European Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), where ISO 10993-23 is a harmonized reference
• NMPA device registration in China, referencing the GB/T 16886 series of national standards
• Submissions to other jurisdictions, including Japan, Canada, Australia, and Brazil, which accept ISO 10993-based biological evaluation packages
• Research and development screening of candidate polymers, adhesives, coatings, hydrogels, and elastomers before design freeze
• Change control and requalification following material substitution, supplier changes, manufacturing process modifications, or sterilization changes
• Risk management documentation under ISO 14971, where irritation data feed the biological hazard analysis

FAQ

Is skin irritation testing mandatory for devices that only contact intact skin briefly?

For limited-duration intact-skin contact devices, ISO 10993-1 permits a documented rationale to omit certain endpoint tests, particularly when the device is made from well-characterized materials with an established history of safe use. However, adhesives, gels, coatings, and colored or fragranced components often trigger irritation testing expectations from regulators, so a case-by-case assessment is recommended.

Can in vitro testing fully replace rabbit irritation studies?

Validated reconstructed human epidermis methods are increasingly accepted as screening tools and, within defined applicability domains, as standalone evidence for certain polymer-based devices. Restrictions on extraction vehicles, extraction conditions, and device types still apply, and confirmatory in vivo testing may be required when results are positive, borderline, or outside the applicability domain.

What is the difference between the PII and the intracutaneous reactivity criterion?

The Primary Irritation Index summarizes dermal patch test responses on a 0 to 8 scale and is interpreted in bands of increasing severity. Intracutaneous reactivity uses a pass/fail comparison: the difference between mean test and control scores should not exceed 1.0. Both approaches are recognized, and selection depends on device contact type and regulatory preference.

Why are two extraction vehicles used?

Polar and non-polar vehicles extract different classes of chemical species. Using both saline-type and oil-type vehicles ensures that water-soluble and lipid-soluble irritants are both captured, providing a worst-case assessment of the leachables profile.

How much sample is required and how long does testing take?

Typical requirements are two to three finished devices or an equivalent mass or surface area per extraction vehicle, plus retention samples for control extract preparation. In vivo studies, including animal acclimation, exposure, and observation, are generally completed within three to four weeks, while in vitro RhE studies can often be completed within one to two weeks, excluding sample preparation and report issuance.

Can historical data be used instead of new testing?

ISO 10993-1 encourages a weight-of-evidence approach in which existing data, literature, chemical characterization by extractables and leachables analysis, and clinical history are evaluated first. New testing is performed only when the existing evidence is insufficient to close the biological safety question for the specific device and its manufacturing process.